Avadel Pharma (AVDL) Reports Q4 Loss of $0.46/Share
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/17/2026
- L3Harris CEO steps down amid conduct review, shares drop
- S&P 500 inches lower as Middle East tensions outweigh tech gains
- Reddit leads social media platforms in revenue growth per user
- Northland Upgrades Astera Labs (ALAB) to Outperform, 'Right Time, Customers, and Products'
- H.C. Wainwright Reiterates Buy Rating on Soluna (SLNH)
Avadel Pharmaceuticals Reports Fourth Quarter and Full Year 2018 Financial Results
March 15, 2019 7:00 AM EDTDUBLIN, Ireland, March 15, 2019 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a company focused on developing FT218 for sleep disorders, today announced its financial results for the fourth quarter and full year of 2018.
We have recently announced a restructuring and other activities to focus our efforts and resources toward advancing our lead clinical-stage asset, FT218, said Greg Divis, Interim Chief Executive Officer of Avadel. Cost savings generated by the restructuring, along with hospital product cash flow, are expected to extend our cash runway into 2021. In conjunction with the restructuring, we have engaged a third-party to... More
